INTRODUCTION
Fibromyalgia syndrome (FM) is a very prevalent rheumatic disease. Widely underestimated and rarely diagnosed, it strikes between 2 and 4% of the general population [1] , with a clear predominance in females. In Italy, disease prevalence is 4.1% in the general population (6.9% in women and 0.3% in men) [1] . FM shows a bimodal pattern of incidence: a first peak between 25 and 35 years and a second between 45 and 55 years [2] . This syndrome is characterized by widespread chronic pain, tenderness in muscles and deep tissues, and fatigue accompanied by other non-specific symptoms, including sleep disturbances. In particular, the widespread pain of FM is a disabling condition and can become quite marked when evoked by digital pressure at tender points (TPs). Research suggests that pain in FM syndrome is associated with a generalized alteration in the central somatosensory system [3, 4] . Central sensitization is likely sustained by neuroinflammatory processes triggered by microglia activation [5] . These data suggest that the cross-talk between nervous and immune systems plays a fundamental role in the onset and progression of chronic pain in patients with FM [6] .
Diagnosis is still carried out according to decreased muscle strength [9] , headache, irritable bowel syndrome, paresthesias, cramps and fasciculations, cognitive disorders, anxiety-depressive syndrome, blurred vision, and unusual thermal, tactile, auditory, visual and/or olfactory sensations [10, 11] . Although trigger conditions such as strong psycho-physical stress [12, 13] or febrile illness (often of viral origin) have been suggested, the pathogenesis of FM remains largely unknown. Several hypotheses have been advanced, which have led to the definition of FM as a neuroimmune-endocrine disorder, whereby the molecular mechanisms of neurotransmitter dysfunction are associated with more obvious neurological deficits [10, [14] [15] [16] [17] [18] [19] [20] .
The etiopathogenic and clinical complexity of FM requires a multidisciplinary approach based on multimodal therapeutic strategies that include also non-pharmacological interventions [10, 14] . In particular: reduce peripheral nociceptive input (muscle relaxants, anti-inflammatory agents, physical therapy); reduce or prevent central sensitization; treat co-morbid conditions that contribute to maintaining a high pain threshold [17] . At present, treatment of FM favors the use of centrally acting anti-epileptics and antidepressants, since drugs acting peripherally (e.g., corticosteroids, non-steroidal anti-inflammatory drugs) would be less effective [21] . Anti-epileptics such as gabapentin and pregabalin (PGB) have been used in FM with especially encouraging results:
30% reduction in pain intensity in about half of patients and 50% in about one-third [22] .
Further, PGB was effective in persistent pain refractory to common analgesics and sleep disorders [23] . Antidepressants, by improving the quality-quantity of sleep, can decrease some associated symptoms such as fatigue and gastrointestinal disorders, thereby contributing to the optimization of analgesia in patients with FM [24] . Among antidepressants, inhibitors of serotonin/norepinephrine reuptake (e.g., duloxetine [DLX]) were more efficacious than serotonin reuptake inhibitors [25, 26] . Optimal results were achieved by integrating treatments to take advantage of potential drug synergism while assuring a better safety profile, owing to the use of each drug at its lowest effective dose [27] .
An As compared to naïve PEA (particle size profile ranging between 100 and 700 lm), micronized and ultramicronized PEA differs in their particles size profile (2-10 lm and 0.8-6 lm at most, respectively). Micronization and ultramicronization processes yield a different crystalline structure with higher energy content and smaller particle size which result in better diffusion and distribution of these molecules compared to the naïve form, and thus superior biological efficacy [30, 36] . The study aim was to investigate, whether PEA-m and PEA-um would provide additional clinical benefit in controlling pain in patients with FM, in multimodal therapy.
METHODS
The complete study was conducted on a total of 80 patients with FM, divided into two separate arms, as described below. 
Prospective Uncontrolled Study
Patients with a diagnosis of FM according to the ACR criteria were enrolled. PEA-um and PEA-m were added at the third month of this existing therapeutic regimen based on DLX ? PGB, for a total duration of 3 months (PEA-um tablets 600 mg/bid in the first month, and PEA-m tablets 300 mg/bid in the next 2 months).
Patients were selected based on their superimposability in terms of number and therapeutic doses to those enrolled in the retrospective observational study.
In all patients, the main outcomes were TPs and Visual Analog Scale (VAS). In both steps of the study (retrospective and prospective), a qualified rheumatologist performed the TP examination in a standardized way. The examiner used exactly the same instructions for each subject and used a dolorimeter with a pressure of 4 kg/cm 2 to ensure equivalence in application of pressure to the TPs. VAS, from 0 = no pain to 10 = the worst pain, was used to measure pain score.
Statistical Analysis
A multivariate analysis generalized linear mixed model (GLMM) was carried out to test whether the clinical benefit of PEA was independent of ongoing treatment with DLX ? PGB. Gender, treatment, time, and interaction time ''treatment'' were used as covariate to test the efficacy. Single comparison was evaluated using
Tukey-Kramer adjusted test.
RESULTS

Retrospective Observational Study
In this step, we analyzed 45 patients (37 women, 8 men; mean age 47 ± 5 years, range 40-52 years). At baseline, the patients showed the following characteristics: number of positive TPs equal to 14/18 with presence of evoked pain in 3/3 and intensity of pain on the VAS was equal to 6.9 ± 0.09. They received a combination therapy comprising DLX ? PGB. diminished from 3/3 to 1/3, and the VAS scale mean score went from 6.9 ± 0.09 to 4.0 ± 0.11. After 6 months of therapy, evoked pain remained at 1/3, positive TPs were further reduced to 4/18, and the VAS scale mean score reached the value of 3.0 ± 0.12.
Prospective Observational Study
The patient baseline characteristics were: number of positive TPs equal to 14/18 with presence of evoked pain in 3/3 and intensity of Fig. 1) , the evoked pain was equal to 1/3 and the VAS scale mean score diminished down from 3.7 ± 0.17 (month 3) to 1.9 ± 0.17 (month 6) (Fig. 2) . The effects of the combination therapy DLX ? PGB ? PEA-um and PEA-m achieved significance (p\0.0001) for VAS and TPs comparisons ( Table 2 ). In the analysis of variance, all included variables were significant. The addition of PEA to the therapy with DLX ? PGB provided a significant clinical benefit independent of concomitant therapies The VAS continually decreased over time; the difference between treated and controls was largest at month 6 (p\0.0001; Fig. 2 ). None of the study patients discontinued therapy before the end of the treatment period because they did not experience either systemic/local adverse events or intolerance to PEA.
DISCUSSION
One of the most noteworthy clinical features of FM is widespread pain that, at particular points Moreover, it should be considered that, when this study was conducted, there were no available data on the combination of PEA ? PGB on FM outcomes. Therefore, this was designed as an exploratory study to evaluate the potential effects of a multimodal pharmacotherapy in FM. The study results offer some clinical information regarding the potential benefits of adding PEA to DLX ? PGB in patients with FM, indicating the need for further research into combinations with different drug classes. Again, further studies would need to be conducted to evaluate the benefits of combining these treatments in the general FM population.
Our research suggests the efficacy and safety of PEA in the treatment of pain associated with 
